Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Kushen Injection for reduction of radiotherapy-related adverse reactions in lung cancer
ChiCTR-IPR-14005482Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound kushen injection in bronchial carcinoma (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Incidence and severity of radiotherapy-related adverse reactions. Started Oct 2014; status: recruiting.
02
Drugs
compound kushen injection
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR-IPR-14005482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005482.